Revium Recovery, Inc. engages in the manufacturing of beverages. The company is headquartered in New York City, New York. The company went IPO on 2001-08-22. is a pre-clinical stage biopharmaceutical company. The company develops technologies and drug-delivery technological platforms. Its pipeline encompasses antibiotics for antimicrobial-resistant bacteria, immune checkpoint inhibitor adjuvant for solid tumors, and an immunization platform. The Company, through its subsidiary, LipoVation Ltd., develops a portfolio of NLP-based pharmaceutical candidates and plans to complete the development and commercialization of a series of medical technologies including: Nanoparticles-based formulation of a potent antibiotic which, based on in vitro and in vivo animal models studies, shows promising potential in combating severe life-threatening antibiotic-resistant bacteria (Nano-Mupirocin); Novel adjuvant to cancer therapies: a nanoparticles-based formulation of angiotensin receptor blockers for intravenous administration (Nano-Candesartan), and Liposomal Protein-Loaded Technology - an approach in immunization through nano particle-based vaccines.
Follow-Up Questions
Quelle est la performance du prix de l'action RVRC ?
Le prix actuel de RVRC est de $0, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Revium Rx ?
Revium Rx appartient à l'industrie N/A et le secteur est N/A
Quel est la capitalisation boursière de Revium Rx ?
La capitalisation boursière actuelle de Revium Rx est de $0
